Brand or generic? new study tests palbociclib versions in advanced breast cancer
NCT ID NCT07493291
First seen Apr 17, 2026 · Last updated May 01, 2026 · Updated 2 times
Summary
This study compares the effectiveness and safety of brand-name palbociclib (Ibrance) versus a local generic version in 100 Iraqi women with advanced HR+/HER2- breast cancer. Participants receive either the brand or generic drug alongside hormone therapy. The main goal is to see how long the cancer stays under control before it progresses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CDK4/6 INHIBITOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anbar cancer center
Ramadi, Al-Anbar Governorate, 10003, Iraq
Conditions
Explore the condition pages connected to this study.